Generics giants jostle over pain drug


The US Food and Drug Administration (FDA) has approved the first batch of generic competitors to Pfizer’s non-steroidal anti-inflammatory Celebrex (celecoxib). Teva received approval for its 50, 100, 200 and 400mg doses, and Mylan also had its 50mg dose approved. Actavis, which was also in the running, is yet to receive final approval for any of its celecoxib generics.

The agency has also granted Teva 180 days’ market exclusivity for all but the 50mg form, under US provisions designed to encourage generic competition. Both Mylan and Actavis have attempted to sue the FDA for this decision, which Mylan has called an ‘unprecedented error’ and Actavis described in a statement as ‘arbitrary, capricious and contrary to law’. The court denied Mylan’s injunction, but the company has signalled its intention to appeal that decision.

Mylan has also negotiated an agreement with Pfizer to launch its generic versions in December 2014, or earlier under certain conditions. All three companies now have such agreements in place.


Related Content

Generics triumph in anti-inflammatory patent battle

25 April 2014 Business

news image

Pfizer settles deals to allow copycat celecoxib

Business roundup

27 January 2012 Business

news image

Industry news, February 2012

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent